XOMA Corp XOMA Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125

09:08 EDT 1 Aug 2017 | BioPortfolio Reports

XOMA Corp XOMA Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


XOMA Corp Xoma, formerly Xoma Ltd, is a biopharmaceutical company that discovers, develops antibodybased therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 formerly LFA 102 is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp Key Recent Developments

May 18,2017: XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development
May 09,2017: XOMA Reports First Quarter 2017 Financial Results
Mar 16,2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 16,2017: XOMA Appoints Matthew Perry to its Board of Directors
Nov 09,2016: XOMA Reports Third Quarter 2016 Achievements and Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: XOMA Corp XOMA Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125


More From BioPortfolio on "XOMA Corp XOMA Financial and Strategic SWOT Analysis Review [Report Updated: 12072017] Prices from USD $125"

Quick Search

Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Searches Linking to this Story